Patents Examined by Gillian A Hutter
-
Patent number: 11969417Abstract: The invention relates to a composition comprising a HIF-1a activity potentiating agent for use in a method of preventing or treating hair loss, wherein the HIF-1a activity potentiating agent is an iron chelator, preferably Deferiprone. The invention further relates to a composition for topical application, comprising a HIF-1a activity potentiating agent that is an iron chelator. Furthermore, the invention relates to a method for cosmetic treatment or prevention of hair loss, comprising topical application of a composition comprising a HIF-1a activity potentiating agent that is an iron chelator to an area of skin.Type: GrantFiled: January 28, 2020Date of Patent: April 30, 2024Assignee: TOMORROWLABS GMBHInventors: Dominik Thor, Dominik Duscher
-
Patent number: 11944627Abstract: The present disclosure provides methods for treating hematological malignancies and Ewings sarcoma using menin inhibitors. Compositions for use in these methods are also provided.Type: GrantFiled: March 22, 2018Date of Patent: April 2, 2024Assignee: KURA ONCOLOGY, INC.Inventors: Francis Burrows, Linda V. Kessler, Liansheng Li, Pingda Ren, Yi Wang, Tao Wu, Jingchuan Zhang
-
Patent number: 11939308Abstract: The present disclosure provides a novel biphenyl derivative compound or a pharmaceutically acceptable salt thereof. The biphenyl derivative compound or pharmaceutically acceptable salt thereof according to the present disclosure is a compound that increases Nm23-H1/NDPK activity and can inhibit cancer metastasis and growth. Thus, it exhibits excellent effects not only on the prevention, alleviation and treatment of cancer, but also on the suppression of cancer metastasis.Type: GrantFiled: May 30, 2019Date of Patent: March 26, 2024Assignee: EWHA University—Industry Collaboration FoundationInventors: Kong Joo Lee, Hee-Yoon Lee, Je Jin Lee, Hwang Suk Kim, Ji-Wan Seo, Hongsoo Lee, Ji Soo Shin, Bo-kyung Kim
-
Patent number: 11925652Abstract: A composition of at least one cannabinoid in a specific amount, and at least one primary terpene in a specific amount, where a total terpenes to total cannabinoids weight/weight ratio in the composition is from about 0.05 to about 1.0.Type: GrantFiled: February 28, 2023Date of Patent: March 12, 2024Assignee: BUZZELET DEVELOPMENT AND TECHNOLOGIES LTDInventors: Noa Raz, Aharon M. Eyal
-
Patent number: 11866439Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.Type: GrantFiled: May 30, 2019Date of Patent: January 9, 2024Assignee: PRAXIS PRECISION MEDICINES, INC.Inventors: Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella, Kiran Reddy, Marion Wittmann
-
Patent number: 11787772Abstract: The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with a pain, a depressive disorder, a mood disorder, an anxiety disorder, borderline personality disorder, opioid addiction, or opioid withdrawal symptoms by administering the compound to the subject.Type: GrantFiled: March 15, 2018Date of Patent: October 17, 2023Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Andrew Kruegel, Dalibor Sames, Jonathan A. Javitch
-
Patent number: 11744808Abstract: Cepharanthine, Repirinast, Ifenoprodil Hemitartrate, Bromantane, Actarit, Lobenzarit, Irsogladine, Istradefylline, Trapadil, Bemithyl, and are used for treating or prophylaxis of lobular inflammation, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis in a subject.Type: GrantFiled: July 3, 2019Date of Patent: September 5, 2023Assignee: ALGERNON PHARMACEUTICALS INC.Inventor: Mark Williams
-
Patent number: 11738013Abstract: Provided are methods for treating hepatitis B virus infections by administering a NS5A inhibitor, NS5B inhibitor, a NS3 inhibitor, or combinations thereof.Type: GrantFiled: May 11, 2017Date of Patent: August 29, 2023Assignee: Gilead Sciences, Inc.Inventors: Anuj Gaggar, G. Mani Subramanian
-
Patent number: 11730734Abstract: The invention relates to kinase inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating or preventing herpesvirus infection and/or herpesvirus-associated diseases and disorders.Type: GrantFiled: September 12, 2017Date of Patent: August 22, 2023Assignee: University of Florida Research Foundation, IncorporatedInventors: Christopher Fisher, Terri G. Edwards, David C. Bloom
-
Patent number: 11718630Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.Type: GrantFiled: October 27, 2022Date of Patent: August 8, 2023Assignee: The Regents of the University of CaliforniaInventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
-
Patent number: 11661418Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.Type: GrantFiled: December 4, 2020Date of Patent: May 30, 2023Assignee: OMEROS CORPORATIONInventors: Neil S. Cutshall, Jennifer Lynn Gage, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Thomas L. Little, Markus Metz, Peter Kurt Nollert Von Specht, Loren Michael Price, Jennifer Tsoung
-
Patent number: 11660275Abstract: Provided is a combination agent that combines N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide with an AMPA-type glutamate receptor antagonist such as 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one or 2-fluoro-6-(3-fluoro-8-oxo-7-(pyridin-3-yl)-7,8-dihydro-6H-pyrano[3,2-b:5,4-b?]dipyridin-9-yl)benzonitrile, and it has potential for use as a therapeutic agent for epilepsy.Type: GrantFiled: March 18, 2019Date of Patent: May 30, 2023Assignee: Eisai R&D Management Co., Ltd.Inventors: Hiroyuki Higashiyama, Hisashi Wakita, Yoshimasa Ito, Yoshihide Osada
-
Patent number: 11633401Abstract: The present technology provides methods for treating pancreatic cancer using a MEK inhibitor and a CDK4/6 inhibitor. Also disclosed herein are methods for increasing patient responsiveness to chemotherapeutic and/or immunotherapeutic regimes for pancreatic cancer. Kits for use in practicing the methods are also provided.Type: GrantFiled: July 3, 2019Date of Patent: April 25, 2023Assignee: Memorial Sloan Kettering Cancer CenterInventors: Marcus Ruscetti, John P. Morris, IV, Scott Lowe
-
Patent number: 11628156Abstract: Provided is a therapeutic product comprising at least one cannabinoid; at least one primary terpene; and at least 5% by weight of a non-cannabinoid, non-terpene carrier, wherein said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said product is about 0.1 to about 1.0. Also provided is a method of treating certain conditions and/or symptoms in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a product comprising at least one primary terpene. Further provided is a therapeutic product comprising a primary terpene blend, wherein said primary terpene blend comprises five or less terpenes, and wherein each one of those terpenes, where present, independently comprises at least 10% of the total terpene content.Type: GrantFiled: January 21, 2020Date of Patent: April 18, 2023Assignee: BUZZELET DEVELOPMENT AND TECHNOLOGIES LTDInventors: Noa Raz, Aharon M. Eyal
-
Patent number: 11622956Abstract: Described is a cannabinoid-terpenoid solution (CTS) and method of treating a disease state or condition in animals other than humans via cannabinoid-terpenoid therapy. The CTS includes a unique combination of cannabinoids, terpenoids (terpenes), and a lipophilic carrier to allow safely and effectively treat the animal.Type: GrantFiled: June 26, 2020Date of Patent: April 11, 2023Assignee: RCR BiopharmaInventor: Irena Raskin
-
Patent number: 11613535Abstract: There is disclosed a compound, a pharmaceutical composition and a method of cancer treatment with an improved Myc inhibitor compound. More specifically, there is disclosed an improved compound having with improved solubility, improved binding characteristics and better efficacy and therapeutic activity inhibiting c-MYC wherein the improved compound comprises a tri-substituted pyridine having a thiazoyl moiety at position R1 versus an earlier disclosed genus of tri-substituted pyridine structures.Type: GrantFiled: July 8, 2019Date of Patent: March 28, 2023Assignee: The Scripps Research InstituteInventor: Kim D. Janda
-
Patent number: 11603376Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.Type: GrantFiled: March 25, 2021Date of Patent: March 14, 2023Assignee: The Regents of the University of CaliforniaInventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
-
Patent number: 11602546Abstract: A composition inhibiting MEIS proteins. The MEIS proteins are effective in proliferation of hematopoietic stem cells. A formulation capable of easily passing through the cell membrane and perform its activity in the cell, and can inhibit MEIS activity in a dose dependent manner. The combination includes isolated cells, medium, growth factors and MEISi inhibitor. The isolated cells are isolated from mouse bone marrow, human bone marrow and human umbilical cord blood. The medium has a pH value of 7.2 and contains bovine serum albumin, recombinant insulin, transferrin, 2-mercaptoethanol and IMDM medium. The growth factors are hematopoietic stem cell factor SCF, fetus liver tyrosine kinase-3 ligand Flt3L, and thrombopoietin. A chemical formula of the MEISi-1 is 4-[2-(benzylamino)-2-oxoethoxy]-N-(2,3-dimethylphenyl) benzamide. A chemical formula of MEISi-2 is 4-hydroxy-N?-[(Z)-(2-oxonaphthalen-1-ylidene)methyl] benzohydrazide.Type: GrantFiled: September 25, 2017Date of Patent: March 14, 2023Assignee: YEDITEPE UNIVERSITESIInventors: Fatih Kocabas, Raife Dilek Turan
-
Patent number: 11576878Abstract: Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.Type: GrantFiled: April 16, 2020Date of Patent: February 14, 2023Assignee: LABOMED PHARMACEUTICAL COMPANY S.A.Inventors: Georgios Liolios, Ioannis Psarrakis
-
Patent number: 11554124Abstract: The purpose of the invention is to provide a novel hematopoiesis-promoting agent and a medicament comprising the hematopoiesis-promoting agent as an active ingredient for preventing or treating anemia, in particular refractory anemia. The present invention provides a hematopoiesis-promoting agent comprising an S-adenosylmethionine synthase inhibitor.Type: GrantFiled: February 25, 2019Date of Patent: January 17, 2023Assignee: TOHOKU UNIVERSITYInventors: Kazuhiko Igarashi, Hiroki Kato, Yusho Ishii, Chi Long Nguyen, Hideo Harigae